[Treatment strategy for high-grade B-cell lymphoma].

High-grade B-cell lymphoma (HGBL) is a newly defined entity in the latest WHO classification. HGBL is classified into two categories as follows: HGBL with MYC and BCL2 and/or BCL6 [so-called "double-hit" (DH)] rearrangements; and HGBL, not otherwise specified. At present, no standard induction treatment regimen and treatment strategy, including the role of upfront stem cell transplantation, exist for patients with HGBL. As the prognosis of patients with HGBL, especially those with DH, who were treated with R-CHOP therapy is relatively poor, recently several retrospective and prospective studies have been conducted. Thus, this session aims to review the clinical data and consider the reasonable treatment strategy for patients with HGBL.